

Special Issue

The Immunotherapy Against Swine Disease

Message from the Guest Editors

The Special Issue, entitled "The Immunotherapy Against Swine Disease", aims to explore recent advancements in immunotherapeutic strategies targeting viral and bacterial diseases that significantly affect both the swine industry and overall animal health. Emphasizing the importance of innovative approaches, we invite studies focused on vaccine development, monoclonal antibodies, and host immune modulation as essential components in enhancing swine health outcomes. This Special Issue serves as a platform for researchers to present their findings, examine emerging technologies, and address the challenges inherent in implementing immunotherapy within swine populations. We encourage submissions that encompass both basic and applied research, particularly those investigating immunological responses, the efficacy of various therapeutic modalities, and comparative analyses. Through this initiative, our goal is to stimulate collaboration and deepen our understanding of effective immunotherapeutic interventions in the swine industry. We look forward to receiving your contributions.

Guest Editors

Prof. Dr. Changlong Liu

Prof. Dr. Fei Gao

Prof. Dr. Yanhua Li

Deadline for manuscript submissions

30 June 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/229743

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).